关于“抗PD-1治疗后大疱性类天疱疮：一项评估对肿瘤反应和生存结局影响的回顾性病例对照研究”的评论 - Suppr | 超能文献

Comment on "Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes".

作者信息

Apalla Zoe, Lazaridou Elizabeth, Lallas Aimilios

机构信息

Second Dermatology Department, Medical School, Aristotle University of Thessaloniki, Greece.

Second Dermatology Department, Medical School, Aristotle University of Thessaloniki, Greece.

出版信息

J Am Acad Dermatol. 2022 Dec;87(6):e249. doi: 10.1016/j.jaad.2020.04.174. Epub 2020 May 13.

DOI:10.1016/j.jaad.2020.04.174

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Comment on "Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes".关于“抗PD-1治疗后大疱性类天疱疮：一项评估对肿瘤反应和生存结局影响的回顾性病例对照研究”的评论

J Am Acad Dermatol. 2022 Dec;87(6):e249. doi: 10.1016/j.jaad.2020.04.174. Epub 2020 May 13.

2

Reply to: "Comment on 'Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes'".回复：“对‘抗PD-1治疗后大疱性类天疱疮：一项评估对肿瘤反应和生存结果影响的回顾性病例对照研究’的评论”

J Am Acad Dermatol. 2022 Dec;87(6):e245-e248. doi: 10.1016/j.jaad.2020.05.023. Epub 2020 May 15.

3

Bullous pemphigoid after anti-programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes.抗程序性死亡-1治疗后发生大疱性类天疱疮：一项评估对肿瘤反应和生存结果影响的回顾性病例对照研究。

J Am Acad Dermatol. 2022 Dec;87(6):1400-1402. doi: 10.1016/j.jaad.2019.12.068. Epub 2020 Jan 10.

4

Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.PD-1 抑制剂不良事件报告系统中与 PD-1 抑制剂相关的大疱性类天疱疮不良事件的比例分析。

Expert Opin Drug Saf. 2019 Jul;18(7):623-633. doi: 10.1080/14740338.2019.1619693. Epub 2019 May 22.

5

Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.抗 PD-1 和抗 PD-L1 治疗相关的大疱性疾病：一项回顾性分析，评估了临床和组织病理学特征、频率以及对癌症治疗的影响。

J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. Epub 2018 Jul 17.

6

Response to: "Missed induced bullous pemphigoid: When the anamnesis is the cure," a comment on "Missed drug-induced bullous pemphigoid leads to longer immunosuppression than recognized cases: A 9-year retrospective review".对《漏诊的药物性大疱性类天疱疮：当病史即治疗方法》的回应，这是对《漏诊的药物性大疱性类天疱疮导致免疫抑制时间长于已确诊病例：一项9年回顾性研究》的评论。

J Am Acad Dermatol. 2020 Sep;83(3):e223-e224. doi: 10.1016/j.jaad.2020.05.060. Epub 2020 May 19.

7

Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study.抗PD-1/PD-L1治疗相关大疱性类天疱疮的临床、生物学和组织学特征：一项全国性回顾性研究。

J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e511-e514. doi: 10.1111/jdv.17253. Epub 2021 Apr 13.

8

Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.二肽基肽酶-4 抑制剂与第二代磺酰脲类药物起始治疗时大疱性类天疱疮风险评估。

JAMA Dermatol. 2020 Oct 1;156(10):1107-1114. doi: 10.1001/jamadermatol.2020.2158.

9

Drugs associated with bullous pemphigoid. A case-control study.与大疱性类天疱疮相关的药物。一项病例对照研究。

Arch Dermatol. 1996 Mar;132(3):272-6.

10

Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.一名黑色素瘤患者在帕博利珠单抗诱导的大疱性类天疱疮皮损部位出现皮肤转移。

Immunotherapy. 2022 Dec;14(17):1377-1382. doi: 10.2217/imt-2022-0113. Epub 2022 Dec 6.

引用本文的文献

1

Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.免疫检查点抑制剂相关的皮肤不良事件：发生机制

Int J Mol Sci. 2024 Dec 26;26(1):88. doi: 10.3390/ijms26010088.

2

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review.免疫检查点抑制剂的皮肤不良事件：文献综述

Dermatol Pract Concept. 2021 Jan 29;11(1):e2021155. doi: 10.5826/dpc.1101a155. eCollection 2021 Jan.